期刊文献+

脑微血管内皮细胞TNFR差异表达对rhTNF开放血肿瘤屏障的影响

Effect of TNFR differentially expressed on brain microvascular endothelial cells for rhTNF open the blood-tumor barrier
下载PDF
导出
摘要 目的观察脑微血管内皮细胞的肿瘤坏死因子受体(TNFR)差异表达对rhTNF开放血肿瘤屏障的影响。方法建立TNFR1/TNFR2高表达的脑微血管内皮细胞株,并与C6胶质瘤细胞一起通过Transwell小室构建体外血肿瘤屏障模型。免疫荧光技术检测脑微血管内皮细胞TNFR的表达水平。荧光分析法测定给予rhTNF后的血肿瘤屏障通透性变化。结果脑微血管内皮细胞的TNFR1高表达时,rhTNF开放血肿瘤屏障的程度最大。而TNFR2高表达时,血肿瘤屏障开放程度与对照组相比无明显差异。结论 rhTNF可能是通过与脑微血管内皮细胞的TNFR1结合而引起血肿瘤屏障开放的。 Objective To observe effect of TNFR differentially expressed on brain microvascular endothelial cells for rhTNF open the blood-tumor barrier.Methods Brain microvascular endothelial cell(BMEC) of TNFR1/TNFR2 highly expression line was established and blood tumor barrier in vitro model with C6 glioma cells through Transwell was built.Using immunofluorescence to detect TNFR expression levels in brain microvascular endothelial cells.Fluorescence analysis method was used to determine blood tumor barrier permeability changes after given the rhTNF.Results Blood-tumor barrier openess reached maximum by rhTNF when TNFR1 high expression on brain microvascular endothelial cells,but high expression of TNFR2 did not cause significant blood-tumor barrier openness than control group.Conclusion rhTNF may combine TNFR1 on brain microvascular endothelial cells and open the blood tumor barrier.
出处 《中风与神经疾病杂志》 CAS CSCD 北大核心 2013年第7期580-582,共3页 Journal of Apoplexy and Nervous Diseases
基金 国家自然科学基金资助项目(No:81101912) 河北省卫生厅科研基金项目(No.20120144) 河北联合大学博士启动基金项目(No.BS09012) 河北联合大学大学生创新性实验计划项目(X2012011) 国家教育部新教师基金项目(No.20102134120007) 辽宁省博士启动基金项目(No.20101109)
关键词 胶质瘤 血肿瘤屏障 TNFR Glioma Blood-tumor barrier TNFR
  • 相关文献

参考文献8

  • 1Harford-Wright E, Lewis KM, Vink R. Towards drug discovery for brain tumours:interaction of kinins and tumours at the blood brain barrier interface[J]. Recent Pat CNS Drug Discov,2011,6( 1 ) :31 -40.
  • 2Thompson EM, Frenkel EP, Neuwelt EA. The paradoxical effect of bevacizumab in the therapy of malignant gliomas [ J ]. Neurology, 2011,76(1) :87 -93.
  • 3Reynolds DS, Morton AJ. Changes in blood-brain barrier permeability following neurotoxic lesions of rat brain can he visualised with trypan blue [ J 1. J Neurosci Methods, 1998,79 ( 1 ) : 115 - 121.
  • 4Fisher B, Leighton C, Macdonald D, et al. The dose-volume interac- tion in adult supratentorial low-grade glioma: higher radiation dose is beneficial among patients with partial resection [ J ]. J Neurooncol, 2007,82(2) :165 - 170.
  • 5Gururangan S, Fisher MJ, Allen JC, et al. Temozolomide in Children with progressive low-grade glioma [ J 1. Neuro-oneo1,2007,9 ( 2 ) : 161 - 168.
  • 6Hau P, Koch D, Hundsberger T, et al. Safety and feasibility of long- term temozolomide treatment in patients with high-grade glioma [ J ]. Neurology,2007,68 (9) :688 - 690.
  • 7秦丽娟,薛一雪,张田,谷艳婷,张文丽,孙娜,王建军,贾永森,郭静.缓激肽诱发胶质瘤细胞释放的肿瘤坏死因子-α对体外血瘤屏障的影响[J].中国肿瘤临床,2012,29(12):822-825. 被引量:2
  • 8Van Ostade X,Vandenabeele P,Everaerdt B,et al. Human TNF mu- tants with selective activity on the p55 receptor[ J]. Nature, 1993, 361 (6409) :266 -269.

二级参考文献10

  • 1C6t6 J, Savard M, Bovenzi V, et al. Selective tumor blood-brain barrier opening with the kinin B2 receptor agonist [Phe(8)psi(CH(2) NH)Arg(9)]-BK in a F98 glioma rat model: an MRI study[J]. Neu- ropeptides, 2010, 44(2): 177-185.
  • 2On LJ, Gu YT, Zhang H, et al. Bradykinin-induced blood-minor barrier opening is mediated by tumor necrosis factor-alpha[J]. Neu- rosci Lett 2009, 450 (2): 172-175.
  • 3Hurst RD, Fritz LB. Properties of an immortalized vascular endothelial/ glioma cell co-culture model of the blood-brain barrier [J]. j Cell Physiol, 1996, 167(1): 81-88.
  • 4Harford-Wright E, Lewis KM, Vink R. Towards drug discovery ibr brain tumours: interaction of kinins and tumours at the blood brain barrier interface[J]. Recent Pat CNS Drug Discov, 2011, 6(1):31-40.
  • 5Thompson EM, Frenkel EP, Neuwelt EA. The paradoxical effect of bevacizumab in the therapy of malignant gliomas[J]. Neurology, 2011, 76(1): 87-93.
  • 6Raslan F, Schwarz T, Meuth SG, et al. Inhibition of bradykinin re ceptor B1 protects nfice from focal brain injury by reducing blood - brain barrier leakage and intlammation[J]. J Cerebr Blood Flow Me tabol, 2010, 30(8): 1477-1486.
  • 7Zweckberger K, Plesifila N. Anatibant, a selective non-peptide bra- dykinin B2 receptor antagonist, reduces intracranial hypertension and histopathological damage after experimental traumatic brain injury[J]. Neurosci Lett, 2009, 454(2):115-117.
  • 8Om LJ, Gu YT, Zhang H, et al. Bradykinin-induced blood-tumor barrier opening is mediated by tumor necrosis factor-alpha0]. Neu- rosci Lett, 2009, 450(2): 172-175.
  • 9Wachtel M, Bolliger MF, Ishihara H, et al. Down-regulation of oc- cludin expression in astrocytes by tumour necrosis factor (TNF) is mediated via TNF type-1 receptor and nuclear factor-kappaB acti- vation[J],J Neurochem, 2001, 78(1): 155-162.
  • 10Kazumasa M, Mikio F, Yoshida Y, et al. Molecular architecture of tight junctions of periderm differs from that of the maculae occludentes of epidermis[J].J Invest Dermatol, 2002, 118(6): 1073-1079.

共引文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部